Research
Hormonal
Adiponectin inhibits spontaneous and catecholamine-induced lipolysis in non-obese humans via AMPK-dependent mechanisms, and its levels are decreased in obesity.
Adiponectin, an adipokine, helps inhibit fat breakdown in non-obese individuals. In obesity, adiponectin levels drop, potentially contributing to altered lipid metabolism. Maintaining healthy adiponectin levels through weight management and exercise is beneficial for metabolic health.
GoodSupportsHIGH confidence
Adiponectin has been shown to inhibit spontaneous and catecholamine-induced lipolysis in human adipocytes of non-obese subjects through AMPK-dependent mechanisms. In contrast to most adipokines, which are markedly up-regulated in obesity, adipose tissue expression and circulating concentrations of adiponectin are decreased in both overweight and obesity.
Why this rating
The paper reviews multiple studies on adiponectin's effects.
Source
Regulation of adipocyte lipolysis
Gema Frühbeck et al. · Nutrition Research Reviews · 2014
DOI 10.1017/s095442241400002x
narrative_reviewCited 427×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Insulin is the primary hormonal inhibitor of lipolysis, acting by activating phosphodiesterase-3B to lower cAMP levels and preventing hormone-sensitive lipase (HSL) activation.Strong
- Catecholamines (adrenaline and noradrenaline) stimulate lipolysis by binding to beta-adrenergic receptors, increasing cAMP, and activating Protein Kinase A (PKA) to phosphorylate Hormone-Sensitive Lipase (HSL) and Perilipin.Strong
- Caffeine and methylxanthines stimulate adipocyte lipolysis by antagonizing A1-adenosine receptors and inhibiting phosphodiesterase, thereby increasing intracellular cAMP levels.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →